The Global Market for ADHD Therapeutics is Projected to Cross US$25 Billion by 2022
Growing Awareness Over the Importance of Mental Healthcare
and Establishment of Clinical Practice Guidelines for Diagnosis and Treatment to
Drive the ADHD Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.
GIA
launches comprehensive analysis of industry segments, trends, growth drivers,
market share, size and demand forecasts on the global Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics market. The global market for ADHD Therapeutics is projected to
cross US$25 billion by 2022, driven
by growing public awareness and gradual dissipation of social stigma associated
with psychiatric disorders and the implementation of formal clinical practice
guidelines for diagnosis and treatment.
Attention Deficit Hyperactivity Disorder (ADHD),
also known as Attention Deficit Disorder (ADD)/ Hyper Kinetic Disorder (HKD) or
Neuropsychiatric Disorder, is one of the most common diseases afflicting nearly
5.3% to 7.1% of children and adolescents as well as 3.4% of adults globally. With
increased awareness, easy access to behavioral healthcare services, changes in
diagnostic criteria and improved ADHD medications, the market continues to
witness growth. Although historically made up of children and adolescents,
adults currently represent the fastest growing patient cluster for ADHD
therapeutics largely because of improvements in behavioral diagnostics and evaluation
techniques which reveal a surprisingly high percentage of patients with childhood
ADHD carry clinically significant symptoms well into adulthood. Addressable market
opportunity therefore is poised to receive a boost from the development of algorithm
and guidelines for the evaluation, diagnosis, treatment, and monitoring of ADHD
in adults. Formal guidelines added in the latest edition of Diagnostic Statistical
Manual of Mental Disorders (DSM) will therefore boost diagnosis rates for adult
patients.
Although currently mired in uncertainty over
Trump's proposed healthcare reforms, the Affordable Care Act (Obamacare Act) until
now played a major role in encouraging growth in the ADHD drugs market in the
United States. The act makes it obligatory for insurance providers to provide
coverage for mental health services which also includes assessment of
behavioral disorder and treatments. This has led to increased number of parents
seeking medical aid for their children afflicted with ADHD, which they
previously were unable to due to cost concerns. In view of the huge unmet needs
in terms of treatment options, and better
diagnostic tests, pharma companies are stepping up their investments in the development of
novel new generation drugs for ADHD.
As stated by the new
market research report on Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, the United States accounts for the bulk of global
revenues. Asia-Pacific ranks as one of the fastest growing markets with a CAGR
of 7.3% over the analysis period, led by factors such as growing population and
a parallel increase in healthcare burden, development of healthcare
infrastructure; establishment of several self-help groups and support systems as
a result of growing awareness of hyperactivity as a behavioral disorder; and gradual
easing of barriers to mental healthcare access such as cost and affordability
and availability of qualitied mental health professionals.
Major
players covered in the report include Alcobra Ltd., Amarantus Bioscience
Holdings, Inc., Amedra Pharmaceuticals LLC, Curemark, LLC., Eli Lilly and
Company, Intellipharmaceutics International, Inc., Janssen Global Services,
LLC, Mallinckrodt PLC, Mylan N.V., Neos Therapeutics, Inc., Neurovance, Inc.,
Noven Pharmaceuticals, Inc., Pfizer Inc., Shire plc, Supernus Pharmaceuticals,
Inc., and Tris Pharma, Inc., among others.
The
research report titled "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics:
A Global Strategic Business Report"
announced by Global Industry Analysts Inc., provides a comprehensive review of
market trends, growth drivers, mergers and acquisitions, and other strategic
industry activities of major companies worldwide. The report provides market
estimates and projections for geographic markets, such as the US, Canada, Japan,
Europe, Asia-Pacific, Latin America, and Rest of World.
Global Industry Analysts, Inc. 6150 Hellyer
Ave., San Jose CA 95138, USA, All Rights Reserved.
Comments
Post a Comment